Download GHEC affiliate profile JA Tice August 5, 2014 Name Jeffrey (Jeff) A

GHEC affiliate profile JA Tice August 5, 2014
Name
Affiliations
Narrative
(brief; refer to
detailed
information on
projects and
publications
below)
Goals
Selected
projects and
plans
Collaborators
(selected)
5 key
publications
Teaching
Skills
Substantive
areas
Jeffrey (Jeff) A. Tice, MD
UCSF DGIM, CTSI, ICER, CTAF
Twenty-three years’ experience in the empirical and modeled assessment of the costeffectiveness of dietary fat reduction, CAD screening and interventions, breast cancer,
and hepatitis C. Currently, PI of a contract to provide systematic reviews underlying
cost and value analyses of new technologies with the California Technology Assessment
Forum (CTAF), a program of the Institute for Comparative Effectiveness Research (ICER).
 Expand awareness and utility of cost information in health care policy discussions in
the United States
 Support UCSF global health economics capacity (via GHECon)
 California Technology Assessment Forum: Systematic reviews and cost analysis in
support of a public forum making judgments about the clinical effectiveness and
value of new medical technologies. Currently expanding our cost analysis of
emerging therapies for hepatitis C.
 USPSTF: Cost-utility modeling of aspirin and statins for primary prevention of CAD.
 CHD Policy Model: Modeling the impact of homocysteine lowering therapy on CHD
in the United States.
 CISNET: Collaboration with the BCSC on the optimal use of risk assessment to guide
breast cancer screening technologies.
 Economists & modelers: D Ollendorf (ICER), S Pearson (ICER), S Earnshaw (UNC).
 Clinical & epidemiology researchers: L Goldman (CU), M Pignone (UNC), M Pletcher
(UCSF).
 Ollendorf DA, Tice JA, Pearson SD. The Comparative Clinical Effectiveness and Value
of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection. JAMA internal
medicine. May 5 2014.
 Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower
plasma homocysteine levels for the prevention of coronary heart disease: effect of
grain fortification and beyond. Jama. Aug 22-29 2001;286(8):936-943.
 Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of
cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. Feb 12
2007;167(3):290-295.
 Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the
primary prevention of coronary heart disease events in men: a cost-utility analysis.
Ann Intern Med. Mar 7 2006;144(5):326-336.
 Browner WS, Westenhouse J, Tice JA. What if Americans ate less fat? A quantitative
estimate of the effect on mortality. Jama. Jun 26 1991;265(24):3285-3291.
Established: Intervention and disease modeling, cost-effectiveness, systematic review.
Desired: Costing, improved network meta-analysis.
Established: Breast cancer, coronary artery disease, hepatitis C.
Page 1 of 1